While Twist1 methylation may be a useful biomarker to predict the clinical outcomes as to recurrence and survival in patients with cancers [12, 13, 15], it remains controversial whether or not the Twist1 methylation at the promoter region leads to silencing of the gene. The gene discussed is TWIST1; the disease is cancer.